OraSure Technologies, Inc.
OSUR Healthcare Medical Instruments & Supplies
OraSure Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $115.0 million, down 38.1% from fiscal 2024. In the quarter to June 2026, revenue fell 1.93%, EPS grew 134.6%, free cash flow fell 1.40% and total debt fell 8.27%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow OSUR
OraSure Technologies, Inc. (OSUR) Piotroski F-score
OraSure Technologies, Inc.'s Piotroski F-score for fiscal 2025 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, down from 5 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 3 | (2.00) |
| FY2024 | 5 | (3.00) |
| FY2023 | 8 | 4.00 |
| FY2022 | 4 | 3.00 |
| FY2021 | 1 | (2.00) |
| FY2020 | 3 | 1.00 |
| FY2019 | 2 | (4.00) |
| FY2018 | 6 | 1.00 |
| FY2017 | 5 | (4.00) |
| FY2016 | 9 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (15.57%) | (4.05%) | Fail | 0 |
| Positive operating cash flow | (49.02m) | 27.37m | Fail | 0 |
| Rising return on assets | (15.57%) | (4.05%) | Fail | 0 |
| Cash flow above net income | 19.71m | 46.87m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 6.58 | 9.95 | Fail | 0 |
| No new shares issued | 73,485,000 | 74,434,000 | Pass | 1 |
| Rising gross margin | 41.90% | 42.72% | Fail | 0 |
| Rising asset turnover | 0.26 | 0.39 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| EMBC Embecta Corp. compare | 7 |
| UTMD Utah Medical Products, Inc. compare | 6 |
| PDEX Pro-Dex, Inc. compare | 6 |
| ANGO AngioDynamics, Inc. compare | 5 |
| KRMD KORU Medical Systems, Inc. compare | 5 |
| NNNN Anbio Biotechnology compare | 5 |
| ZJYL Jin Medical International Ltd. compare | 4 |
| SMTI Sanara MedTech Inc. compare | 4 |
| OSUR OraSure Technologies, Inc. | 3 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover